PL366802A1 - Zastosowanie inhibitorów IL-18 do leczenia i/lub zapobiegania chorobie serca - Google Patents

Zastosowanie inhibitorów IL-18 do leczenia i/lub zapobiegania chorobie serca

Info

Publication number
PL366802A1
PL366802A1 PL02366802A PL36680202A PL366802A1 PL 366802 A1 PL366802 A1 PL 366802A1 PL 02366802 A PL02366802 A PL 02366802A PL 36680202 A PL36680202 A PL 36680202A PL 366802 A1 PL366802 A1 PL 366802A1
Authority
PL
Poland
Prior art keywords
inhibitors
prevention
treatment
heart disease
heart
Prior art date
Application number
PL02366802A
Other languages
English (en)
Other versions
PL213568B1 (pl
Inventor
Charles Dinarello
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Yolande Chvatchko
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of PL366802A1 publication Critical patent/PL366802A1/pl
Publication of PL213568B1 publication Critical patent/PL213568B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL366802A 2001-01-29 2002-01-28 Zastosowanie inhibitora IL-18 oraz zastosowanie wektora ekspresyjnego PL213568B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29

Publications (2)

Publication Number Publication Date
PL366802A1 true PL366802A1 (pl) 2005-02-07
PL213568B1 PL213568B1 (pl) 2013-03-29

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
PL366802A PL213568B1 (pl) 2001-01-29 2002-01-28 Zastosowanie inhibitora IL-18 oraz zastosowanie wektora ekspresyjnego

Country Status (32)

Country Link
US (1) US20040234523A1 (pl)
EP (1) EP1355668B1 (pl)
JP (2) JP4860897B2 (pl)
KR (1) KR100857376B1 (pl)
CN (1) CN1326562C (pl)
AR (1) AR032422A1 (pl)
AT (1) ATE380558T1 (pl)
BG (1) BG66483B1 (pl)
BR (1) BR0206819A (pl)
CA (1) CA2435466C (pl)
CY (1) CY1107203T1 (pl)
CZ (1) CZ305653B6 (pl)
DE (1) DE60224004T2 (pl)
DK (1) DK1355668T3 (pl)
EA (2) EA006767B1 (pl)
EE (1) EE05534B1 (pl)
ES (1) ES2295332T3 (pl)
HK (1) HK1062810A1 (pl)
HR (1) HRP20030609A2 (pl)
HU (1) HU229164B1 (pl)
IL (2) IL157024A0 (pl)
ME (1) ME00549B (pl)
MX (1) MXPA03006776A (pl)
NO (1) NO331083B1 (pl)
PL (1) PL213568B1 (pl)
PT (1) PT1355668E (pl)
RS (1) RS51125B (pl)
SI (1) SI1355668T1 (pl)
SK (1) SK287620B6 (pl)
UA (1) UA80676C2 (pl)
WO (1) WO2002060479A1 (pl)
ZA (1) ZA200305439B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335336B (pl) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
EP1331943A4 (en) 2000-10-11 2005-01-26 Viron Therapeutics Inc NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
PL1891088T3 (pl) 2005-06-10 2012-03-30 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
AU2008324814B2 (en) * 2007-11-05 2013-05-16 Solventum Intellectual Properties Company Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MX2016002719A (es) * 2013-09-05 2016-09-06 Ab2 Bio Sa Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
MY194040A (en) 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
ATE310528T1 (de) * 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
DE69736984T2 (de) * 1996-12-06 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des interleukin-1-beta konvertierenden enzyms
CA2282845A1 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
AU3876600A (en) * 1999-03-16 2000-10-04 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
AU4213500A (en) * 1999-04-09 2000-11-14 Cytovia, Inc. Caspase inhibitors and the use thereof
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
TWI335336B (pl) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
UA87658C2 (uk) * 2000-05-05 2009-08-10 Апплайд Резеч Системз Арс Холдинг Н.В. Застосування il-18 як діагностичного маркера серцевої недостатності
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CA2435466A1 (en) 2002-08-08
HU229164B1 (en) 2013-09-30
NO20033228D0 (no) 2003-07-16
PL213568B1 (pl) 2013-03-29
CN1326562C (zh) 2007-07-18
HUP0303306A3 (en) 2005-12-28
AR032422A1 (es) 2003-11-05
NO331083B1 (no) 2011-10-03
DE60224004T2 (de) 2009-07-23
NO20033228L (no) 2003-09-26
ME00549B (me) 2011-10-10
JP4860897B2 (ja) 2012-01-25
ZA200305439B (en) 2004-07-15
BG66483B1 (bg) 2015-03-31
WO2002060479A1 (en) 2002-08-08
ES2295332T3 (es) 2008-04-16
HK1062810A1 (en) 2004-11-26
ATE380558T1 (de) 2007-12-15
EA010180B1 (ru) 2008-06-30
EP1355668A1 (en) 2003-10-29
PT1355668E (pt) 2008-01-04
IL157024A (en) 2014-02-27
BG108128A (bg) 2004-11-30
MXPA03006776A (es) 2003-10-24
EE200300328A (et) 2003-10-15
JP2004522748A (ja) 2004-07-29
UA80676C2 (en) 2007-10-25
CN1499982A (zh) 2004-05-26
EP1355668B1 (en) 2007-12-12
DE60224004D1 (de) 2008-01-24
JP2009102354A (ja) 2009-05-14
SI1355668T1 (sl) 2008-06-30
EA200501549A1 (ru) 2006-04-28
CA2435466C (en) 2012-04-03
US20040234523A1 (en) 2004-11-25
RS51125B (sr) 2010-10-31
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
CZ305653B6 (cs) 2016-01-27
EA200300844A1 (ru) 2003-12-25
KR100857376B1 (ko) 2008-09-05
CZ20032335A3 (en) 2004-07-14
HRP20030609A2 (en) 2005-06-30
BR0206819A (pt) 2004-02-03
IL157024A0 (en) 2004-02-08
EE05534B1 (et) 2012-04-16
SK10892003A3 (sk) 2004-02-03
HUP0303306A2 (hu) 2004-01-28
YU57803A (sh) 2006-05-25
DK1355668T3 (da) 2008-05-05
EA006767B1 (ru) 2006-04-28
CY1107203T1 (el) 2012-11-21

Similar Documents

Publication Publication Date Title
SI1487541T1 (sl) Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
HUP0401127A3 (en) Treatment and diagnosis of macrophage disease
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
EP1455778A4 (en) METHODS OF TREATING PERIPHERAL NEUROVASCULAR MALAYS
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
PL372928A1 (pl) Zastosowanie osteoprotegeryny do leczenia i/lub zapobiegania chorobie przebiegającej z włóknieniem
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
HRP20030609A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
GB0213869D0 (en) The treatment of pain
EP1406648A4 (en) USE OF ANGIOTENSIN I DERIVATIVE AGENT FOR THE TREATMENT AND PREVENTION OF INFECTIOUS HEART DAMAGE AND DISEASES
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
EP1409734A4 (en) DIAGNOSIS AND TREATMENT OF CANCER
GB0101146D0 (en) Treatment of skin conditions
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EP1669085A4 (en) THERAPEUTIC AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE
AU2002365654A8 (en) Treatment of diseases via the skin
GB0108622D0 (en) Treatment and prevention of tissue damage
GB0121046D0 (en) The diagnosis and treatment of airways disease
EP1463525A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMOR